See more : Zhongzhu Healthcare Holding Co.,Ltd (600568.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Imago BioSciences, Inc. (IMGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imago BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Waja Company (9560.SR) Income Statement Analysis – Financial Results
- Central Bancompany, Inc. (CBCY) Income Statement Analysis – Financial Results
- Getinge AB (publ) (GETI-B.ST) Income Statement Analysis – Financial Results
- Legend Upstar Holdings Limited (MDICF) Income Statement Analysis – Financial Results
- DigitalOcean Holdings, Inc. (DOCN) Income Statement Analysis – Financial Results
Imago BioSciences, Inc. (IMGO)
About Imago BioSciences, Inc.
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.26M | 14.90M | 8.24M |
| General & Administrative | 10.26M | 3.18M | 2.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 10.26M | 3.18M | 2.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.52M | 18.07M | 10.66M |
| Cost & Expenses | 42.52M | 18.07M | 10.66M |
| Interest Income | 314.00K | 48.00K | 38.00K |
| Interest Expense | 314.00K | 48.00K | 38.00K |
| Depreciation & Amortization | 6.00K | 1.00K | -208.00K |
| EBITDA | -42.52M | -17.78M | -10.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.00M | -18.07M | -10.66M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.00K | 242.00K | -246.00K |
| Income Before Tax | -42.31M | -17.83M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 3.00K | 0.00 |
| Net Income | -42.31M | -17.83M | -10.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -3.16 | -1.33 | -0.81 |
| EPS Diluted | -3.16 | -1.33 | -0.81 |
| Weighted Avg Shares Out | 13.38M | 13.38M | 13.38M |
| Weighted Avg Shares Out (Dil) | 13.38M | 13.38M | 13.38M |
Imago BioSciences Stock Surges. It's Being Bought by Merck.
Merck will pay $36 in cash for each share of Imago BioSciences.
Imago BioSciences stock soars after Merck bids more than 100% premium to buy the biotech
Shares of Imago BioSciences Inc. IMGO, -3.87% soared toward an eight-month high in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms (MPNs) and other bone marrow diseases announced an agreement to be acquired by Merck &...
Merck to Acquire Imago BioSciences, Inc.
RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under...
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that...
Imago BioSciences to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Young Rienhoff, Jr.,...
Why Earnings Season Could Be Great for Imago BioSciences (IMGO)
Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's...
Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ImagoBioSciences--Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
7 Companies Begin Trading. Here's How They're Doing.
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
Source: https://incomestatements.info
Category: Stock Reports